Scarica l'app Stockscreener
3.76
9.30%
0.32
Dopo l'orario di chiusura:
3.77
0.01
+0.27%
Precedente Chiudi:
$3.44
Aprire:
$3.4
Volume 24 ore:
292.77K
Relative Volume:
2.61
Capitalizzazione di mercato:
$120.95M
Reddito:
$4.06M
Utile/perdita netta:
$-50.22M
Rapporto P/E:
-2.3231
EPS:
-1.6185
Flusso di cassa netto:
$-25.37M
1 W Prestazione:
-8.52%
1M Prestazione:
-23.89%
6M Prestazione:
+12.57%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$3.263
$3.79
Intervallo di 1 settimana:
$2.42
$4.37
Portata 52W:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
Nome
Insight Molecular Diagnostics Inc
Settore
Industria
Telefono
949-409-7600
Indirizzo
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
3.76 | 120.95M | 4.06M | -50.22M | -25.37M | -1.6185 |
TMO
Thermo Fisher Scientific Inc
|
491.46 | 182.57B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
191.12 | 135.26B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
569.55 | 45.24B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
115.48 | 32.63B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
304.24 | 29.85B | 3.17B | 642.63M | 516.49M | 10.77 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-28 | Iniziato | Lake Street | Buy |
| 2022-05-24 | Downgrade | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | Iniziato | Stephens | Overweight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-03-17 | Ripresa | Needham | Buy |
| 2021-01-07 | Aggiornamento | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | Iniziato | BTIG Research | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | Reiterato | The Benchmark Company | Speculative Buy |
| 2020-07-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | Iniziato | Needham | Buy |
| 2019-02-13 | Iniziato | Piper Jaffray | Overweight |
| 2019-01-29 | Aggiornamento | Janney | Neutral → Buy |
| 2018-12-19 | Ripresa | Lake Street | Buy |
Mostra tutto
Insight Molecular Diagnostics Inc Borsa (IMDX) Ultime notizie
Stock List: Research Stocks from Around the World - GuruFocus
BTIG reiterates Neutral rating on Insight Molecular stock By Investing.com - Investing.com Canada
BTIG reiterates Neutral rating on Insight Molecular stock - Investing.com
Insight Molecular (IMDX) Soars 22.36% During Intraday Rally — What’s Driving the Market Turbulence? - Bitget
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
IMDX CFO’s RSUs Vest as Company Withholds Shares for Taxes - Stock Titan
IMDX (IMDX) VP Yang sees RSUs vest while shares withheld for taxes - Stock Titan
CEO at Insight Molecular (IMDX) vests 47,170 RSUs with no share sale - Stock Titan
Insight Molecular Diagnostics Inc (OCX) Stock Price Quote Today & Current Price Chart - Capital.com
Trade Insight Molecular Diagnostics IncOCX CFD - Capital.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst - Yahoo! Finance Canada
Insight Molecular Diagnostics Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Needham reiterates Buy on Insight Molecular stock, $9 target By Investing.com - Investing.com India
Insight Molecular Diagnostics Inc. Q4 2025 earnings preview - MSN
Needham reiterates Buy on Insight Molecular stock, $9 target - Investing.com
Insight Molecular Diagnostics outlines $2B annual market opportunity and signals rapid commercialization push for GraftAssureDx - MSN
Earnings call transcript: Insight Molecular Diagnostics Q4 2025 reveals strategic milestones - Investing.com India
Insight Molecular Diagnostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Insight Molecular Diagnostics (NASDAQ:IMDX) Soars on 285% Revenue Beat and Key FDA Submission - ChartMill
Insight Molecular Diagnostics: Q4 Earnings Snapshot - crossville-chronicle.com
IMDX: Revenue doubled and net loss narrowed as focus shifted to transplant diagnostics and kit commercialization - TradingView
IMDX: FDA submission of GraftAssureDx and strong clinical data set stage for 2026 commercialization - TradingView
Insight Molecular 2025 10-K: Revenue $4.06M, Net Loss $50.22M - TradingView
Insight Molecular Diagnostics posts Q4 2025 results; revenue $1.1M in quarter, $4.1M full year - TradingView
Insight Molecular Diagnostics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - MarketScreener
Insight Molecular Diagnostics (IMDX) files GraftAssureDx with FDA and reports 2025 loss - Stock Titan
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results - taiwannews.com.tw
IMDX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Molecular Diagnostics Market Is Going to BoomKey Factors Driving Unstoppable Growth - openPR.com
IMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference - MarketScreener
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference - The Manila Times
Oncocyte : to Begin Trading on the Nasdaq Stock Market on March 8, 2021 - marketscreener.com
iMDx CEO, CFO to join Needham conference after March 26 results - Stock Titan
HTGMQ (HTG Molecular Diagnostics) PNK at $0.0001 19 Mar 2026: top gainer insight - Meyka
Analysts Offer Insights on Healthcare Companies: Neurosense Therapeutics Ltd. (NRSN), Assertio Therapeutics (ASRT) and LENSAR (LNSR) - The Globe and Mail
IMDXInsight Molecular Diagnostics Inc. Latest Stock News & Market Updates - Stock Titan
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Capital And GraftAssureDx Milestones - Yahoo Finance
Certain Restricted Stock Units of Insight Molecular Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026. - marketscreener.com
Certain Warrants of Insight Molecular Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2026. - marketscreener.com
Insight Molecular Diagnostics (IMDX) Advances with GraftAssure T - GuruFocus
Insight Molecular Diagnostics Inc Highlights New Peer-Reviewed Study Demonstrating GraftAssure Assay Technology Superiority - marketscreener.com
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score - The Manila Times
Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score - Bitget
Insight Molecular Diagnostics Nears FDA Submission for Kidney Transplant Rejection Test Kit - Clinical Lab Products
Insight Molecular Diagnostics Nears FDA Submission with GraftAssureDx Milestones - Zenopa
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission - Bitget
Insight Molecular Diagnostics completes key milestones advancing Graftassuredx toward FDA submission - marketscreener.com
Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission - TradingView
Insight Molecular Diagnostics Inc Azioni (IMDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.17%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):